Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer Subtypes
Research in breast cancer is focused on evaluating available antibody-drug conjugates (ADCs) and oral selective estrogen receptor degraders (SERDs) outside of the metastatic setting, which could greatly improve patient outcomes in HER2-positive and triple-negative disease, according to Christie J. Hilton, DO. “The hope is that [we can] eventually move some of these great agents that … [Read more…]